Stocks in Uptrend After Recent Declines Ready to Bounce

 BullPower
 
  BullPower
 
Follow  Message
 
 
 
BullPower charges through the market, spotlighting analyst upgrades and downgrades that signal key opportunities. With sharp insights and a bullish edge, BullBoost guides investors to smarter, profit-driven decisions.
 

•  28 Oct 2025
 

•   ABBV  
   
  -0.05%
•   ALKS  
   
  +0.26%
•   CAN  
   
  0.00%
•   XEL  
   
  -0.21%

$ALKS caught my attention first. Trading at $31.00 against a $32.23 target, this biotech just crushed third quarter expectations with EPS of $0.49 beating by $0.19 and revenue exceeding estimates by nearly $38 million. Despite these strong results, the stock has pulled back over the past ten days with negative momentum of 0.19. The company raised full-year guidance and is advancing its pipeline with promising phase two data for alixorexton in narcolepsy. Volume spiked to 4.96 million shares, more than double the average, showing institutional interest around earnings. With an RSI of 55.21 and trading right at its 20-day moving average of $30.00, the technical setup looks clean. The earnings beat plus raised guidance creates a fundamental cushion, and the stock sits only 4% from target with a clear catalyst path. This presents a solid short-term opportunity worth considering now.

$XEL at $79.82 tells a steadier story. The utility is experiencing modest declines ahead of earnings, with ten-day and five-day slopes both at negative 0.14. The data center demand narrative provides structural growth, but storm costs will pressure near-term margins. Trading just above its 20-day moving average with an RSI of 53.58, the technical picture remains neutral. The upside to target is only 1.4%, making this more suitable for patient, income-focused positions rather than quick momentum trades. Not the most compelling immediate opportunity.

$CAN offers the highest risk and reward profile. At $1.45 with a $2.06 target, the bitcoin mining equipment maker just launched its latest machine. Volume exploded to 114.38 million shares versus a 72.71 million average around the announcement. The stock holds above both its 20-day and 50-day moving averages despite recent weakness, with an RSI of 54.38 leaving room to run. The challenge is profitability remains negative, and success depends heavily on bitcoin sentiment. For aggressive traders, the 40% upside to target is tempting, but timing matters critically here. The crypto market needs to cooperate for this to work quickly.

$ABBV rounds out the group at $227.54 with a $250 target. The pharmaceutical giant faces near-term pressure from Humira erosion and R&D charges, though Skyrizi and Rinvoq growth should offset some weakness. The stock is flat on its ten-day slope and down 0.79 over five days, sitting right at its 20-day moving average. With earnings approaching, the setup is cautious. The 10% upside to target exists, but visibility on the quarterly numbers creates uncertainty. This might require waiting for actual results before committing capital.

Bottom line: ALKS offers the most attractive near-term opportunity. The combination of earnings beats, raised guidance, pipeline progress, and a clean technical setup at support creates multiple reasons to be constructive. The 4% upside might seem modest, but the risk-reward framework works when you have fundamental catalysts backing a technically sound entry point. For more aggressive traders willing to stomach volatility, Canaan 40% upside potential could pay off if bitcoin momentum returns, but that's a speculation rather than a high-probability setup. Xcel and AbbVie both need more time or clearer catalysts before becoming compelling trades.

View All Headlines